Pacific Biosciences of California, INC.: insider trades · United States · SEC (Form 4)

About Pacific Biosciences of California, INC.

Pacific Biosciences of California, Inc. (NASDAQ: PACB), known commercially as PacBio, is a United States-based life-science technology company headquartered in Menlo Park, California. Founded in the early 2000s, the company built its reputation around high-accuracy genomic sequencing, with a particular focus on long-read technologies that can resolve complex genomic regions, structural variants, repeat expansions and other difficult-to-read areas that are less accessible with conventional short-read methods. PacBio has evolved from a specialist research instrument vendor into a broader sequencing platform company serving academic researchers, genome centers, public-health labs, clinical research groups and industrial customers. PacBio’s business model centers on the design, development and commercialization of sequencing systems, consumables and related services. Its current portfolio includes Revio and Vega for long-read HiFi sequencing, and Onso for short-read sequencing. Revio targets large-scale projects and high-throughput genome analysis, while Vega is positioned as a benchtop long-read solution for labs seeking a simpler workflow and fast, high-quality data generation. Onso extends the portfolio into short-read applications. This combination gives PacBio a differentiated offering across multiple sequencing workflows, while reinforcing its core identity as a precision genomics company. From a competitive standpoint, PacBio is best understood as a niche but influential player in long-read sequencing. Its competitive advantage lies in read quality, completeness and the ability to capture biologically complex information in a single technology workflow. At the same time, it operates in a highly competitive market, facing pressure from both short-read incumbents and alternative long-read platforms. PacBio markets its products in the United States and internationally through direct sales and distribution partners, with commercial reach across Europe, Asia-Pacific and other global regions. Recent company developments have focused on product innovation and operating discipline. In 2025 and 2026, PacBio highlighted advances for Revio and Vega aimed at lowering the cost per genome and expanding multiomic and regulated-research capabilities. The latest quarterly updates also pointed to revenue improvement and a better gross profit trend after a restructuring and strategic refocus on long-read sequencing. For investors, PACB represents a high-risk, innovation-driven US-listed NASDAQ stock with meaningful upside optionality if adoption of long-read genomics continues to broaden in research and applied markets.